“Merck Sharp and Dohme v. Sandoz”

High Court Invalidates Shionogi EPC Patent to HIV Drug “Tivicay” Today in Merck Sharp and Dohme

Networks of innovation: vaccine development at Merck, Sharp & Dohme, and Mulford, 1895–1995

as PTSD was not discovered, but rather was created, or "glued together", "by the practices, technologies and narratives with which it is diagnosed, studied, treated and represented. . ." (p. 5), a claim he convincingly supports in this thought-provoking, though uneven book. Significantly, Young does not deny the "reality" of post-traumatic suffering; rather his goal is to lay bare the construct...

Public Assessment Report Paediatric data COSOPT eye drops solution Dorzolamide Hydrochloride Timolol Maleate Marketing Autorisation Holder: Merck Sharp & Dohme

Introducing Biosimilars into Current Inflammatory Bowel Disease Treatment Algorithms

Disclosure: Prof Simon Travis has been an advisor to, in receipt of educational or research grants from, or an invited lecturer for AbbVie, Amgen, Asahi, Biogen, Boehringer Ingelheim, BMS, Cosmo, Elan, Ferring, FPRT Bio, Genentech/Roche, Genzyme, Glenmark, GW Pharmaceuticals, Lilly, Merck, Novartis, Novo Nordisk, Ocera, Pfizer, Receptos, Shire, Santarus, SigmoidPharma, Synthon, Takeda, Tillotts...

Evangelos Giannitsis 2* Aqp4-igg Immunoprecipitation Assay Optimization

Employment or Leadership: None declared. Consultant or Advisory Role: None declared. Stock Ownership: None declared. Honoraria: E. Giannitsis, Merck Sharp & Dohme, Lilly, Bristol Myers Squibb, GlaxoSmithKline, Roche Diagnostics, and Bayer; H.J. Roth, Merck Sharp & Dohme and Roche Diagnostics. Research Funding: E. Giannitsis received funds and access to assays from Roche Diagnostics. Expert Test...